TherapeuticsMD, Inc.

TXMD

$2.26

+1.12%

2026-09-03 15:23:02 EDT+$0.00

Healthcare

Drug Manufacturers - Specialty & Generic

NASDAQ

Active Trading

TherapeuticsMD, Inc. is a U.S.-based pharmaceutical company dedicated to women's health. Its marketed portfolio includes IMVEXXY, prescribed for moderate to severe dyspareunia; ...

Price Action of TXMD

$2.26

+1.12%+$0.00

High—

Low—

52W High-23.4%

Rel. vol—

Interval

Range3.3h

Volume—SMA5SMA10

—

TherapeuticsMD, Inc. is a pharmaceutical company focused exclusively on women's health, headquartered in Boca Raton, Florida. Founded in 2008, the company develops and commercializes innovative therapies for women, particularly in the areas of menopause, contraception, and prenatal nutrition. Its marketed portfolio includes IMVEXXY, a vaginal insert for moderate to severe ...TherapeuticsMD, Inc. is a pharmaceutical company focused exclusively on women's health, headquartered in Boca Raton, Florida. Founded in 2008, the company develops and commercializes innovative therapies for women, particularly in the areas of menopause, contraception, and prenatal nutrition. Its marketed portfolio includes IMVEXXY, a vaginal insert for moderate to severe dyspareunia; BIJUVA, a bio-identical hormone replacement therapy combining estradiol and progesterone to alleviate vasomotor symptoms; and ANNOVERA, a novel vaginal ring for contraception. In its developmental pipeline, the company is advancing several preclinical candidates, including TX-005HR (transdermal progesterone cream), TX-006HR (transdermal estradiol and progesterone cream), TX-007HR and TX-008HR (transdermal patches), and TX-009HR (oral progesterone and estradiol). Beyond these, the company produces and distributes branded and generic prescription prenatal vitamins under the vitaTrue, vitaPearl, vitaMedMD, and BocaGreenMD Prena1 labels. These products reach consumers through wholesale and retail pharmacy distributors. Financially, the company has experienced challenges, with negative net income and EBITDA margins, but maintains a relatively strong current ratio and low debt levels. The company is led by CEO Marlan D. Walker, and its leadership team includes other key executives. The company's mission is to advance the health of women and champion awareness of their unique healthcare needs.ExpandCollapse

Founded

2008

Employees

CEO

Marlan D. Walker

Full Name

TherapeuticsMD, Inc.

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

ROE

-0.80%

Market Cap

$0.03B

Current Ratio

3.22

WACC

6.94%

ROIC

-32.32%

Contact Information

https://www.therapeuticsmd.com

561 961 1900

951 Yamato Road, Boca Raton, FL 33431

Key Metrics of TXMD

Snapshot

Latest / TTM · 6 periods

Market Cap

$26.16M

ROCE

-11.8%

EV / EBITDA

-5.37x

+1.0% YoY

FCF Yield

11.9%

-0.9% YoY

Cash Conversion Cycle

-131.5d

Current Ratio

3.22

Quick take

TTM —

No major risk flags in selected headline metrics.

Financial Highlights of TXMD

Profitability trend

Latest / TTM · 6 periods

Gross Margin

89.9%

Net Margin

-6.6%

P/E Ratio

-120.21x

n/a

Debt / Equity

0.20

n/a

Current Ratio

3.22

Dividend Yield

0.0%

Understanding

TTM —

Interest coverage is weak

Calendar of TXMD

Upcoming

Dec 31, 2026
FY2026 · Estimated annual results
Est. EPS $0.17 · Revenue $9.30M · 1 analysts
Dec 30, 2027
Q4 FY2027 · Estimated results
Est. EPS $-3.04 · Revenue $23.20M · 1 analysts
Dec 31, 2027
FY2027 · Estimated annual results
Est. EPS $0.19 · Revenue $9.50M · 1 analysts
Mar 30, 2028
Q1 FY2028 · Estimated results
Est. EPS $-0.57 · Revenue $26.80M · 1 analysts

Recent history

Aug 11, 2026
Q2 FY2026 · Results reported
EPS $0.01 · Revenue $869000.00
View filing
May 12, 2026
Q1 FY2026 · Results reported
EPS $0.01 · Revenue $724000.00
View filing
Mar 30, 2026
FY2025 · Annual results
EPS $-0.05 · Revenue $3.02M
View filing
Nov 12, 2025
Q3 FY2025 · Results reported
EPS $0.01 · Revenue $784000.00
View filing
Aug 12, 2025
Q2 FY2025 · Results reported
EPS $0.05 · Revenue $952000.00
View filing
May 13, 2025
Q1 FY2025 · Results reported
EPS $-0.06 · Revenue $393000.00
View filing

Financial Statements of TXMD

5Y Trend (Revenue, Earnings, FCF)

Metric	Latest	YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.	QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).	$3.0M	+71.6%	+20.0%
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.	$-569000	+73.9%	+63.2%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.	+100.0%	0.0%	-37.9%
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).	-139.4%	+49.3%	+7.5%
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.	-18.8%	+84.8%	+35.9%
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.	$2.4M	+231.1%	-17.7%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.	+80.2%	+93.0%	-31.5%
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.	22.7%	-13.5%	-5.2%
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.	3.02x	+57.1%	+3.7%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.	$37.7M	-3.0%	-0.1%

Actual vs Estimate

A Dec 31Q Dec 30

Metric	Annual (A vs E)	Annual Surprise	Quarter (A vs E)	Quarter Surprise
EPS Surprise	-0.05 vs 0.16	-130.8%	0.01 vs -3.04	+100.4%
Revenue Surprise	$3.0M vs $9.2M	-67.2%	$869000 vs $23.2M	-96.3%

Insider Transactions of TXMD

Acquisitions (A)

Since Feb 18, 2025

Disposals (D)

Since Feb 18, 2025

Monthly shares of acquisitions/disposals with close price trend (shared daily price source)

Insider Trading Snapshot

Date	Executive	Title	Security	Side	Shares	Price
Dec 23, 2025	Thompson Tommy G	director	Common Stock	A	8,400	$1.67
Nov 3, 2025	Thompson Tommy G	director	Restricted Stock Units	A	8,500	—
Nov 3, 2025	Naughton Gail K	director	Restricted Stock Units	A	8,500	—
Nov 3, 2025	Collins Cooper C.	director	Restricted Stock Units	A	8,500	—
Nov 3, 2025	Walker Marlan D	officer: Chief Executive Officer	Non-Qualified Stock Option (right to buy)	A	67,492	$1.15

Leadership Team of TXMD

2 executives

Name	Title	Compensation	Gender	Year Born	Status
Marlan D. Walker	Chief Executive Officer	USD 511,137	Male	1976	Active
Joseph A. Ziegler	Principal Financial & Accounting Officer	USD 120,000	Male	1974	Active

Recent News of TXMD

GuruFocus8/11/2026Neutral

TherapeuticsMD Announces Second Quarter 2026 Financial Results

TherapeuticsMD, Inc. (âTherapeuticsMDâ or the âCompanyâ) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financia

Business Wire8/11/2026Neutral

TherapeuticsMD Announces Second Quarter 2026 Financial Results

BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the three months ended June 30, 2026. Second Quarter 2026 Financial Results Net Income from Continuing Operations Net income from continuing operations totaled $164 thousand, compared to net income of $545 thousand for the second quarter of 2025. License Revenues from Continuing Operations The Com.

Historical Employee Count of TXMD

Current

Change

+0.00%

Minimum

Maximum

416

Recent Filings

Report Date	Employees	Form Type	Filing Date	SEC Filing
Dec 31, 2025	1	10-K	Mar 30, 2026	View
Dec 31, 2024	1	10-K	Mar 27, 2025	View
Dec 31, 2023	1	10-K	Mar 29, 2024	View
Dec 31, 2022	1	10-K	Apr 7, 2023	View
Dec 31, 2021	416	10-K	Mar 23, 2022	View

Related stocksDrug Manufacturers - Specialty & Generic

Browse all US stocks →

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer

TherapeuticsMD, Inc.